Suchergebnisse

While open innovation has been increasingly adopted in developed countries, firms from emerging markets such as Brazil markedly fall behind this trend. Our understanding of the reasons behind this phenomenon remains nevertheless limited, since most research focuses on the industrialized world. In this paper, we aim to inspire the academic community to investigate the issue of why companies from emerging economies such as Brazil have limited open innovation strategies, when they need to draw on external partners as to overcome the institutional, resource and capability constraints they are subject to. We build on the argument that latecomer firms in emerging economies need to actively use open innovation more than ever, as to overcome internal rigidities and spur the innovative resources and capabilities required for the digital transformation and for addressing grand societal challenges. In reviewing current research on openness and especially in the Brazilian setting, we contend that it is a relevant empirical context to study, giving the potential to uncover unique mechanisms and theoretical relations by asking (and possibly answering) novel research questions. Building on a conceptual framework that links various implementation levels of open innovation, we identify themes that are either less well researched or contested and thereby suggest challenges and opportunities for future research.

Recent European Union (EU) initiatives and legislation have considerably increased public access to clinical trials data (CTD). These developments are generally much welcomed for the enhancement of science, trust, and open innovation. However, they also raise many questions and concerns, not least at the interface between CTD transparency and other areas of evolving EU law on the protection of trade secrets, IPRs, and privacy. This article focuses on privacy issues and on the interrelation between developments in transparency and the EU's new General Data Protection Regulation 2016/679 (GDPR). More specifically, this article examines: (1) the origins and rationales of EU transparency regulations, including the incidents and concerns that have shaped them; (2) the features and implications of the GDPR which are relevant in the context of clinical trials; and (3) the risk for tensions between the GDPR and the policy goals of CTD transparency, as well as implications for data sharing and open innovation. Ultimately, we elaborate on factors that should be carefully considered and addressed to reap the full benefits of CTD transparency.

Recent EU initiatives and legislation considerably increases public access to clinical trials data (CTD). These are generally much welcomed developments for the enhancement of science, trust and open innovation. However, they also raise many questions and concerns. Many of these emerge at the interface of CTD transparency with other areas of evolving EU law concerning the protection of trades secrets, IPRs, and privacy. This paper focuses on the privacy issues by analyzing the interrelation between the transparency developments and the EU's new General Data Protection Regulation 2016/679 (GDPR). More specifically, this paper examines (1) the genesis of the EU transparency regulations, including the incidents, developments and policy concerns that have shaped them; (2) the features and implications of the GDPR in the context of clinical trials; and (3) the practical difficulties and risks for tensions between the GDPR and the policy goals of CTD transparency and open innovation. Ultimately, we stress that such factors must be carefully considered and addressed to reap the full benefits of CTD transparency.

Open innovation is now a widely used concept in academia, business, and policy making. This article describes the state of open innovation at the intersection of research, practice, and policy. It discusses some key trends (e.g., digital transformation), challenges (e.g., uncertainty), and potential solutions (e.g., EU funding programs) in the context of open innovation and innovation policy. With this background, the authors introduce select papers published in this Special Section of California Management Review that were originally presented at the second annual World Open Innovation Conference, held in Santa Clara, California, in December of 2015. ; Open innovation is now a widely used concept in academia, business, and policy making. This article describes the state of open innovation at the intersection of research, practice, and policy. It discusses some key trends (e.g., digital transformation), challenges (e.g., uncertainty), and potential solutions (e.g., EU funding programs) in the context of open innovation and innovation policy. With this background, the authors introduce select papers published in this Special Section of California Management Review that were originally presented at the second annual World Open Innovation Conference, held in Santa Clara, California, in December of 2015.